Roche and Prothena’s Parkinson’s antibody treatment fails at phase 2
The biologic treatment missed the primary endpoint, but did show some improvements in those given the drug and may be better for treating some subgroups than others.
Pipelines
Teva and Sanofi’s IBD drug hits Phase 2 targets
The anti-TL1A antibody allowed significantly more inflammatory bowel disease (IBD) patients to go into remission than those taking placebo treatment.
Orexo and Abera collaborate to develop nasal powder vaccines
The companies will work on the development of an influenza vaccine first.
GSK and Muna Therapeutics partner to develop new treatments for Alzheimer’s
The partnership revolves around Muna Therapeutics’ technology platform, which employs a spatial multi-omics approach to identify and validate new drug targets for neurodegenerative diseases.
Spyre Therapeutics launches Phase 1 trials for its extended half-life IBD therapy
The two anti-TL1A antibodies are being tested in healthy people, with the first participants dosed.
Resolution Therapeutics scores £63.5 million Series B
The UK cell therapy biotech will now advance its first candidate cell therapy to clinical trials for treatment of liver disease.
Aurora Biosynthetics launches to boost RNA therapeutics manufacturing in Asia-Pacific
The new company focuses on producing components needed to manufacture RNA-based therapies for which there is increasing demand.
Eli Lilly expands manufacturing facilities in Ireland with $1.8bn investment
With a new investment in its two manufacturing sites in Ireland, Eli Lilly continues implementing the largest expansion program in the company’s history.
Eli Lilly reports positive phase 3 results for a weekly insulin formulation
New data from the QWINT clinical trial may get Eli Lilly closer to bringing a once-weekly insulin injection to the US, following the FDA’s rejection of Novo Nordisk’s own weekly insulin formulation earlier this year.
BeiGene new flagship biologics manufacturing facility opens after $800M investment
BeiGene, a global oncology company, has announced the opening of its flagship US facility, which will expand the company’s biologics manufacturing capabilities and clinical research and development activities.
Explore how Lonza's experts tackle parenteral drug and bioconjugate development challenges
In the rapidly evolving field of pharmaceuticals, the development of parenteral drugs and bioconjugates presents unique challenges and opportunities.
Third Arc Bio raises $165M series A to develop biologics for cancer and immunology
The oversubscribed fundraising will enable Third Arc Bio to enter the clinic with multiple programs in 2025.
b
Alvotech and Stada debut uzpruvo, the first ustekinumab biosimilar in Europe
Alvotech and Stada launch Stelara biosimilar following European approval earlier this year and expiry of exclusivity rights on the original molecule.
Boehringer Ingelheim and GoodRx undercut Humira by massive 92% with biosimilar
In a bid to make biologic treatments more accessible to patients, Boehringer Ingelheim is harnessing the reach and scale of the prescription savings platform GoodRx to provide its Humira biosimilar adalimumab-adbm at a low price.
Rona Therapeutics raises $35M in series A+ to advance metabolic siRNA therapeutics
The fundraising will support the development of the company’s technology platform for silencing RNA (siRNA), which has the potential to enable dosing patients every six months to treat a wide range of conditions.
Pluri’s CDMO arm takes on ALS and diabetes in cell therapy deal
The contract development and manufacturing organization (CDMO) arm of the Israeli company Pluri will deploy automated and 3D cell expansion technology to produce cell therapies developed by compatriot firm Kadimastem.
Ionis announces positive early results for Angelman syndrome therapy
Ionis Pharmaceuticals antisense therapy for Angelman syndrome achieved good early safety and efficacy results and the company now plans to advance the therapy to phase 3.
Laura Child on passion, career challenges, and advice for young women in life sciences
As a strategic brand consultant at ramarketing, Laura combines her extensive background in clinical research with strategic leadership and creative expression.
Roche’s oral GLP-1 receptor agonist shows promising early weight loss results in phase 1
Roche’s recent $2.7 billion acquisition of Carmot Therapeutics is paying off, with positive results for new oral GLP-1 receptor agonist.
Rentschler opens advanced therapy production line as CDMO demand surges
The contract development and manufacturing organization (CDMO) Rentschler Biopharma has doubled its Current Good Manufacturing Practice (cGMP) global production capacity for complex therapies as its new production line kicks into action in the US.
ReciBioPharm’s Edita Botonjic-Sehic on analytics, AI, and continuous RNA manufacturing
RNA therapeutics have emerged as a transformative approach to treating many conditions, but the industry still typically relies on inefficient batch manufacturing methods.
HilleVax halts development of world’s most advanced norovirus vaccine after phase 2 failure
Results from the NEST-IN1 trial have shown that HilleVax’s vaccine candidate was ineffective at preventing norovirus infections in infants.
CureVac signs agreement with GSK for mRNA vaccines amid layoffs in €1.45B restructuring deal
CureVac has signed a new licensing agreement with GSK shortly after announcing the decision to reduce its workforce by 30% and refocus its research and development priorities.
FDA approves Kisunla for early Alzheimer's treatment amid cognitive decline slowdown
Eli Lilly has finally achieved FDA approval for its monoclonal antibody Alzheimer’s therapy donanemab, bringing new competition to the field for Eisai and Biogen.
ReciBioPharm’s Edita Botonjic-Sehic, on analytics, AI, and continuous RNA manufacturing
RNA therapeutics have emerged as a transformative approach to treating many conditions, but the industry still typically relies on inefficient batch manufacturing methods.
TVM Capital Healthcare invests $35m in Saudi generics and biosimilars
As Saudi Arabia seeks to make its healthcare system more cost-efficient, the private equity firm TVM Capital Healthcare is betting $35 million on the Saudi Arabia-based bio-generics provider Boston Oncology Arabia.
ELRIG UK and The Protein Society partner to advance protein sciences in drug discovery
ELRIG UK, a leading organization in the drug discovery community, has partnered with The Protein Society (TPS) to host a groundbreaking conference on ‘Protein Sciences in Drug Discovery’.
Alnylam's RNAi drug vutrisiran cuts mortality in ATTR-CM by 33% - FDA submission planned
Alnylam’s experimental drug vutrisiran has shown promise for the treatment of transthyretin amyloidosis (ATTR) in a phase 3 clinical trial.
PolTREG’s regulatory T cell therapy shows promise in type-1 diabetes
Results from a phase 1/2 clinical trial revealed that PolTREG’s regulatory T cell (Treg) therapy, PTG-007, was able to restore insulin secretion in children with type-1 diabetes.
Inbar Friedrich Ben-Nun on curiosity, resiliency, and the discovery of what's next.
Director of cell and gene therapy R&D at Lonza, this week's inspiring female is Inbar who we spoke to about her passion for discovering the future and mentor support sparked her early interest in biology and informed her journey of resiliency.
SMC recommends first injectable bispecific for aggressive blood cancer
AbbVie has announced that the Scottish Medicines Consortium (SMC) has approved Tepkinly (epcoritamab) for adults with diffuse large B-cell lymphoma (DLBCL) who have not responded to or have relapsed after at least two prior treatments.
CordenPharma and Certest forge partnership to enhance drug delivery innovations
CordenPharma, a global CDMO manufacturing complex drug substances and lipid nanoparticles (LNPs), has signed a partnership agreement with Certest, a Spanish company specializing in drug delivery and API synthesis.
Three Indian CDMOs ready to seize the BIOSECURE Act opportunity
In the wake of escalating tensions between the United States and China, the Biden Administration is intensifying its strategic focus on biosecurity.
Nucleus RadioPharma secures Series A investment from AstraZeneca
Nucleus RadioPharma, a leading player in the development, manufacturing, and supply chain management of radiopharmaceuticals, has announced a significant milestone with the closing of a Series A extension round, featuring a new investment from AstraZeneca.
Alchemab receives grant to advance promising antibody for Parkinson’s disease
Alchemab Therapeutics, an antibody discovery company focused on identifying antibodies from individuals resilient to disease, has been awarded a grant of $595,000 by The Michael J. Fox Foundation for Parkinson’s Research (MJFF) to propel its Parkinson’s...
BIO 2024 spotlight: Exothera's fast-track solutions for mRNA manufacturing
Darren Leva, chief business officer at Belgium-based CDMO Exothera, is at the forefront of the company’s efforts in advancing mRNA-based therapies.
Could DefiniGEN and Atelerix’s new collaboration revolutionize cell model shipping?
In what could be a significant leap for scientific research and biopharmaceuticals, DefiniGEN and Atelerix have unveiled a new collaboration that allows in vitro cell models to be shipped internationally without freezing or cryopreservation.
Breaking barriers in bioprocessing: An Interview with Enzene Bioscience's CEO
With a rich background in biochemistry and extensive experience in the pharmaceutical industry, Himanshu Gadgil shares insights into Enzene's journey, its innovative approach to biosimilars.
Verona's ensifentrine garners favorable reviews ahead of anticipated US launch for COPD
Verona Pharma has revealed its ongoing preparations for the potential launch of ensifentrine in the US market, slated for the third quarter of 2024 pending FDA approval, expected by June 26, 2024.
BIO International 2024 to focus on partnerships amid new BIOSECURE bill
As the BIO International 2024 trade show approaches, industry insiders anticipate a significant focus on partnership discussions, driven by the pressing financial needs of biotech companies rather than the new BIOSECURE act.
Bora Pharmaceuticals: Driving commercial viability and global growth at BIO 2024
Ahead of Bio International, we had an conversation with Bora Pharmaceuticals to get a glimpse of what they have in store for the event.
How EXO Biologics plans to revolutionize exosome therapy with €16m cash injection
EXO Biologics, a clinical-stage biotech specializing in exosome-based therapies, recently announced the successful raising of €16 million in Series A funding.
Oncology research booms: Global investigator sites double in just five years
Clinical development analytics company Phesi has released a new analysis of global oncology trial investigator sites ahead of attending ASCO 2024 – the American Society of Clinical Oncology’s annual meeting.
Could Innovent Biologics’ mazdutide be a game-changer in type 2 diabetes treatment?
Innovent Biologics has revealed encouraging phase 3 (DREAMS-2) findings for mazdutide, showcasing its superiority over dulaglutide in managing glycemic levels among patients with type 2 diabetes (T2D) in China.
Worldwide Clinical Trials' Peter Benton on the outlook for biopharma funding
Peter Benton is president and CEO of Worldwide Clinical Trials, a full-service global CRO. We spoke with him about his insights into recent trends and factors influencing biopharma investment decisions.
Oxford BioDynamics and Goodbody Clinic launch prostate screening blood test in UK
Oxford BioDynamics, a biotech company specializing in precision medicine tests via the EpiSwitch 3D genomics platform, has partnered with the Goodbody Clinic, a provider of private health testing services.
Cartherics secures European patent for cancer stem cell therapy
Cartherics, a biotechnology company specializing in immune cell therapies for cancer, has announced the granting of its second European patent.
Top pharma executives say lack of funding stalling digital revolution
A new report from Graphite Digital has revealed that 36% of senior leaders in pharma agree that funding is the biggest barrier to digital adoption and transformation, despite increasing spend.
International clinical trials day: Treehill's quest for commercial and clinical success
At the ASCT 2024 conference a few weeks ago, Peter Marks, director of the FDA’s Center for Biologics Evaluation and Research, highlighted a crucial issue in the future of clinical trials.
Endeavor BioMedicines' ENV-101 improves lung function and reverses fibrosis in IPF patients
Endeavor BioMedicines, a clinical-stage biotech company, has announced promising phase 2a trial results for its lead investigational candidate, ENV-101.